Veralipride

Veralipride is a D2 receptor antagonist. It is an alternative antidopaminergic treatment for menopausal symptoms.

Product Specifications

CAS Number

[66644-81-3]

Product Name Alternative

(±) -Veralipride; LIR166

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Veralipride.html

Purity

99.57

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(NCC1N(CC=C)CCC1)C2=CC(S(=O)(N)=O)=CC(OC)=C2OC

Molecular Formula

C17H25N3O5S

Molecular Weight

383.46

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P501

References & Citations

[1]Melis GB, et al. Effects of the dopamine antagonist veralipride on hot flushes and luteinizing hormone secretion in postmenopausal women. Obstet Gynecol. 1988 Nov;72 (5) :688-92.|[2]Carranza-Lira S, et al. Actual status of veralipride use. Clin Interv Aging. 2010 Sep 7;5:271-6.|[3]Valencia MH, e al. Safety of veralipride for the treatment of vasomotor symptoms of menopause. Menopause. 2014 May;21 (5) :484-92.|[4]Franchignoni FP, et al. Parkinson syndrome induced by veralipride. Minerva Ginecol. 1995 Jun;47 (6) :277-9.